Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives

Autor(es)

dos Santos, Aline Martins ^[1] ; Carvalho, Suzana Gonsalves ^[1] ; Meneguin, Andreia Bagliotti ^[1] ; Sabio, Rafael Miguel ^[1] ; Gremiao, Maria Palmira Daflon ^[1] ; Chorilli, Marlus ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: JOURNAL OF CONTROLLED RELEASE; v. 334, p. 353-366, JUN 10 2021.
• Citações Web of Science: 0

Resumo

Colon-targeted oral delivery of drugs remains as an appealing and promising approach for the treatment of prevalent intestinal diseases (ID), such as inflammatory bowel disease (IBD) and colorectal cancer (CRC). Notwithstanding, there are numerous challenges to effective drug delivery to the colon, which requires the design of advanced strategies. Micro- and nanoparticles have received great attention as colon-targeted delivery platforms due to their reduced size and structural composition that favors the accumulation and/or residence time of drugs at the site of action and/or absorption, contributing to localized therapy. The choice by natural polysaccharides imparts key properties and advantages to the nano-in-microparticulate systems to effective colon-specific oral delivery. This review proposes to discuss the physiological barriers imposed by the gastrointestinal tract (GIT) against oral administration of drugs, as well as pathological factors and challenges of the ID for oral delivery of colon-targeted systems. We then provide an updated progress about polysaccharides-based colon-targeted drug delivery systems, including microparticulate, nanoparticulate and nano-in-microparticulate systems, highlighting their key properties, advantages and limitations to achieving targeted delivery and efficacious therapy within the colon. Lastly, we provide future perspectives, towards advances in the field and clinical translation of colon-targeted oral delivery systems for ID therapy. (AU)

• Processo FAPESP: 19/10761-5 - Sistemas multifuncionais destinados à liberação cólon específica do bevacizumabe para o tratamento do Câncer Colorretal
• Beneficiário: Suzana Gonçalves Carvalho
• Modalidade de apoio: Bolsas no Brasil - Doutorado